Showing results (51-60 of 138) with videos related to

Sort By:
Pageof 14
Antimicrobial Resistance and Infection Control|April 17, 2020
Secular trend analysis of antibiotic utilisation in China's hospitals 2011-2018, a retrospective analysis of procurement dataHaishaerjiang Wushouer, Yue Zhou, Xi Zhang, et al.
Antibiotics (Basel, Switzerland)|March 28, 2025
Role of Rifaximin in the Prognosis of Critically Ill Patients with Liver CirrhosisZhaohui Bai, Congcong Li, Yongjie Lai, et al.
BMJ Global Health|July 16, 2021
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in ChinaYichen Zhang, Haishaerjiang Wushouer, Sheng Han, et al.
BMC Geriatrics|June 25, 2024
Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancerZhuo Ma, Man Xu, Mengyuan Fu, et al.
Frontiers in Public Health|July 14, 2022
The Impact of Sanming Healthcare Reform on Antibiotic Appropriate Use in County Hospitals in ChinaLin Hu, Mengyuan Fu, Haishaerjiang Wushouer, et al.
Frontiers in Pharmacology|February 21, 2022
Effects of the Full Coverage Policy of Essential Medicines on Inequality in Medication Adherence: A Longitudinal Study in Taizhou, ChinaZhigang Guo, Liguang Zheng, Mengyuan Fu, et al.
Seminars in Arthritis and Rheumatism|November 11, 2023
Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysisWenliang Dong, Xiaowen Hu, Caiying Wu, et al.
BMJ Open|January 9, 2020
Differences in reimbursement listing of anticancer therapies in China: an observational studyXiaodong Guan, Yichen Zhang, Haishaerjiang Wushouer, et al.
Investigational New Drugs|August 22, 2025
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013-2021Zhizhou Liang, Yu Yang, Yichen Zhang, et al.
Frontiers in Cardiovascular Medicine|November 25, 2022
Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysisSicong Li, Jinshan He, Xinyi Zhang, et al.
Pageof 14